BAVA Bavarian Nordic A/S

Bavarian Nordic Announces Major Shareholder Notification from ATP

Bavarian Nordic Announces Major Shareholder Notification from ATP

Copenhagen, Denmark, April 2, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, received the following major shareholder notification from ATP:

“ATP has increased its ownership in Bavarian Nordic. Subsequently, ATP holds a total of 11.12% of the share capital and voting rights in Bavarian Nordic A/S.”

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit .

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel:

Graham Morrell, Paddock Circle Advisors (US)



Tel:

Company Announcement no. 21 / 2020

Attachment

EN
02/04/2020

Underlying

BAVABavarian Nordic A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE
Free
BAVA Bavarian Nordic...

Bavarian Nordic vil foretage aktietilbagekøb for op til DKK 500 mio.

Bavarian Nordic vil foretage aktietilbagekøb for op til DKK 500 mio. KØBENHAVN, Danmark, 2. december 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag sin hensigt om at iværksætte et engangsprogram for tilbagekøb af egne aktier for op til DKK 500 mio., som skal gennemføres over de næste 12 måneder. Denne beslutning skal ses i lyset af en nuværende stærk likviditetsposition, som følge af det nylige salg af Priority Review Voucher og en fortsat positiv pengestrøm fra driften. Pr. 30. september 2025 udgjorde værdipapirer, kontanter og likvide midler DKK 2.978 mio., hvoraf cirka DKK 800 mi...

December 2, 2025 1 EN
 PRESS RELEASE
Free
BAVA Bavarian Nordic...

Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Mill...

Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months. This decision should be viewed in the context of a current strong cash position, resulting from the recent sale of the Priority Review Voucher and a continued positive cash flow from operations. As of September 30, 2025, securities, cash and cash equivalents were DKK 2,978 million, of which approximately DKK 800 ...

December 2, 2025 1 EN
 PRESS RELEASE
Free
BAVA Bavarian Nordic...

Bavarian Nordic offentliggør delårsregnskab for de første ni måneder a...

Bavarian Nordic offentliggør delårsregnskab for de første ni måneder af 2025 KØBENHAVN, Danmark, 14. november 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab for de første ni måneder af 2025 samt rapporterede på begivenheder for tredje kvartal 2025. Omsætningen i de første ni måneder steg med 32% til DKK 4.793 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 23% til DKK 2.327 mio. sammenlignet med de første ni måneder af 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabie...

November 14, 2025 1 EN
 PRESS RELEASE
Free
BAVA Bavarian Nordic...

Bavarian Nordic Announces Interim Results for the First Nine Months of...

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025 COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and tick-b...

November 14, 2025 1 EN
 PRESS RELEASE
Free
BAVA Bavarian Nordic...

Bavarian Nordic offentliggør ændringer i bestyrelsen

Bavarian Nordic offentliggør ændringer i bestyrelsen KØBENHAVN, Danmark, 13. november 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at formand for bestyrelsen, Luc Debruyne har besluttet at træde tilbage fra bestyrelsen med øjeblikkelig virkning. Bestyrelsen har udnævnt næstformand Anne Louise Eberhard som ny formand for bestyrelsen. “Efter nøje refleksion over både processen og resultatet af det nylige overtagelsesforsøg har jeg besluttet at træde tilbage for at give Bavarian Nordics bestyrelse mulighed for at fokusere på virksomhedens næste udviklingsfase. Jeg har stor b...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch